Lataa...
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
Chimeric antigen receptor (CAR) T-cell therapy has changed the landscape of immunotherapy for B-cell malignancies, including mature B-cell lymphomas. Although two CD19 CAR T-cell products have been commercially approved to treat relapsed/refractory B-cell lymphomas, outcomes in these patients remain...
Tallennettuna:
| Julkaisussa: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727550/ https://ncbi.nlm.nih.gov/pubmed/33275669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000133 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|